RT Journal Article SR Electronic T1 Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 193 OP 195 DO 10.3899/jrheum.141042 VO 42 IS 2 A1 Rossella Reggia A1 Franco Franceschini A1 Angela Tincani A1 Ilaria Cavazzana YR 2015 UL http://www.jrheum.org/content/42/2/193.abstract AB Objective. Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis. Methods. Fifty-one patients treated with SC ABA were included. Clinical data were obtained from clinical charts. Results. Fourteen patients relapsed and needed to return to the IV administration. Neither clinical and laboratory features nor the previous therapies were identified as risk factors for SC formulation inefficacy. Disease activity decreased after the return to IV infusions. Conclusion. SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.